Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6826 to 6840 of 7691 results

  1. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued [GID-TA10221]

    Technology appraisal guidance
    Discontinued

  2. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development [GID-MT567] Expected publication date: TBC

    Medical technologies guidance
    In development

  3. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued [GID-TA10211]

    Technology appraisal guidance
    Discontinued

  4. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued [GID-TA10484]

    Technology appraisal guidance
    Discontinued

  5. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued [GID-TA10416]

    Technology appraisal guidance
    Discontinued

  6. Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

    Discontinued [GID-MT130]

    Medical technologies guidance
    Discontinued

  7. SILK artery reconstruction device (discontinued)

    Discontinued [GID-MT81]

    Medical technologies guidance
    Discontinued

  8. Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

    Discontinued [GID-MT163]

    Medical technologies guidance
    Discontinued

  9. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued [GID-TA10329]

    Technology appraisal guidance
    Discontinued

  10. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued [GID-TA10464]

    Technology appraisal guidance
    Discontinued

  11. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued [GID-TA10635]

    Technology appraisal guidance
    Discontinued

  12. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued [GID-TA10574]

    Technology appraisal guidance
    Discontinued

  13. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

    Technology appraisal guidance
    Discontinued

  14. Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]

    Discontinued [GID-TA10859]

    Technology appraisal guidance
    Discontinued

  15. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

    Antimicrobial prescribing guideline
    Discontinued